Further, using transgenic TCR stimulation in concert with gene edited cells, we found that the PTPN22 risk variant accentuates the response of low-avidity primary human T cells to antigen, implying a key role for these events in the progressive loss of T cell tolerance in human autoimmune diseases associated with this risk allele. The gene discussed is PTPN22; the disease is autoimmune disease.